Abstract Although B chronic lymphocytic leukemia (B-CLL) cells express the alpha chain of the interleukin-2 (IL-2) receptor CD25, little is known about the effect of IL-2 on apoptosis in B-CLL cells. We have shown previously that stimulation of B-CLL cells with a CpG-oligonucleotide induces IL-2 high affinity receptors. In our current work, we analyzed the effect of IL-2 on apoptosis in resting B-
Introduction
B chronic lymphocytic leukemias (B-CLL) have been defined as the accumulation of slow-dividing and longlived B lymphocytes closely resembling small resting B lymphocytes [1] . However, recent research has demonstrated that B-CLL is rather characterized by a dynamic interplay between birth and death [2, 3] .
B-CLL cells seem to rely on supportive signals from the microenvironment, where cellular interactions and cytokines can inhibit apoptosis and promote proliferation [4] . A variety of cell types might be important in this supportive environment, where autologous T cells might provide cytokines involved in proliferation and apoptosis inhibition of malignant B cells [5, 6] .
Interleukin-2 (IL-2) is the prototype cytokine of a cytokine family, which shares the IL-2 gamma chain receptor as a receptor component [7] . Although IL-2 is regarded as a key growth and death factor in antigenactivated T cells and regulatory T cells [8] , it has important functions in other lineages as well [9] .
The reactivity of lymphocytes to Il-2 is mediated by multimeric high affinity receptors (Kd=10 pM) consisting of two obligate signaling subunits, IL-2Rβ (CD122) and γ (CD132), and a variably expressed IL-2Ra (CD25) which regulates affinity for IL-2 [10] .
After heterodimerization of the receptor complexes, IL-2 transduces its signals via different molecules including the Jak-Stat, the MAP kinase, and the PI-3 kinase pathways.
These signaling events usually result in cellular proliferation and inhibition of apoptosis [11] .
B-CLL cells express CD25 at low levels [12] . We and others have demonstrated that upregulation of CD25 in stimulated B-CLL cells results in the formation of functional high affinity receptors [13, 14] . Importantly, IL-2 has demonstrated its potency to increase immunoglobulin secretion, cytokine production, and upregulation of surface molecules in such stimulated cells [15] [16] [17] . IL-2 can be provided by autologous T cells, infiltrating lymph nodes or the bone marrow [18] .
Importantly, IL-2 has been demonstrated to increase B-CLL proliferation and to promote cell cycle progression in a variety of experimental models [16, 17] .
In addition to cellular proliferation, cell accumulation caused by impaired apoptosis is clearly involved in disease progression [2] . However, the role of IL-2 in apoptosis prevention in leukemic B-CLL cells is not well defined.
In the present study, we investigate the potential of IL-2 to inhibit apoptosis in purified resting B-CLL cells and in stimulated leukemic cells expressing high affinity Il-2 receptors. Our results point to a potential role of IL-2 in apoptosis inhibition especially in stimulated B-CLL cells.
Materials and methods
Cell samples After informed consent, peripheral blood was obtained from patients with a diagnosis of B-CLL according to clinical and immunophenotypic criteria. Patients were either untreated or had not received cytoreductive chemotherapy for a period of at least 3 months prior to investigation. At the time of analysis, all patients were clinically stable, free from infectious complications, and undergoing routine clinic out-patient review.
Reagents and antibodies The ODN DSP30 (TCGTC GCTGTCTCCGCTTCTTCTTGCC) was used single stranded, phosphorothioate stabilized, and synthesized by TibMolBiol (Berlin, Germany). IL-2 was obtained from Pepro Tech (London, UK). DiOC6(3) (3,3′-dihexyloxacarbocyanine iodide) was obtained from Molecular Probes (Eugene, OR, USA); AnnexinV-FITC Kit was purchased from Immunotech (Marseille, France). Murine mAbs specific for Mcl-1 and PARP were obtained from Santa Cruz (Santa Cruz, CA, USA). MAbs for Bcl-2 and Bax were obtained from BD Pharmingen (San Diego, CA, USA), and MAb for β-actin is from Sigma (Deisenhofen, Germany). Bcl-xl was from BD Scientific (San Jose, CA, USA); Akt and phospho akt (Ser473), as well as lysates for positive and negative controls, were purchased from Cell Signalling (Danvers, MA, USA). Survivin was obtained from R&D Systems (Minneapolis, MN, USA).
Separation procedures Peripheral blood mononuclear cells (PBMNC) were isolated from heparinized blood samples by centrifugation over a Biocoll separating solution (Biochrom KG seromed®, Berlin, Germany) of 1.077 g/ml density. For separation of B-CLL cells, PBMNC were incubated with anti-CD2 and anti-CD14 magnetic beads (Dynabeads M450, Dynal, Oslo, Norway) according to the manufacturer's instructions. Such prepared B cells from CLL patients were >98% pure as assessed by direct immunofluorescence using a Coulter Epics XL (Coulter, Hamburg, Germany).
Culture conditions Purified leukemic B cells were cultured in RPMI 1640 medium (Gibco, Berlin, Germany) supplemented with 10% fetal calf serum (Biochrom KG seromed®, Berlin, Germany), penicillin/streptomycin 501 U/ml, Na-pyruvate 1 mM, L-glutamine 2 mM, Lasparagine 20 µg/ml, 2-mercaptoethanol 0.05 mM, HEPES 10 mM, and MEM non-essential amino acids 0.7× (Biochrom, Berlin, Germany) at 37°C and 5% CO2 in a fully humidified atmosphere.
Flow cytometric analysis To determine apoptosis-associated parameters, purified B cells were cultured at 1×10 6 cells/ml either in medium alone or together with DSP30 (1 µM) and IL-2 (100 U/ml) at the indicated concentrations. The samples were washed with PBS and resuspended in 500 µl binding buffer (AnnexinV-FITC Kit, Immunotech, Marseille, France), containing 1 µl of AnnexinV-FITC stock and 5 µl of 20 µg/ml PI (propidium iodide) for determination of phosphatidylserine (PS) exposure on the outer plasma membrane. After incubation for 10 min at room temperature in a light-protected area, the specimens were quantified by flow cytometry, using a Coulter Epics XL cytofluorometer, acquiring 5,000 events. Viable cells were both AnnexinV and PI negative. For evaluation of drug-induced apoptosis, apoptosis induction was calculated by subtracting viable cells cultured in medium control from viable cells after incubation with the indicated substance. For these experiments, cells were incubated with LY290042 (Calbiochem, Schwalbach, Germany), rapamycin, or fludarabine (Sigma, Deisenhofen, Germany) as indicated.
To investigate the mitochondrial membrane potential ΔΨ, the cells were incubated with 3,3′-dihexyloxacarbocyanine iodide (DiOC6(3), 20 nM) for 30 min at 37°, washed in PBS, resuspended in 500 µl binding buffer (AnnexinV-FITC Kit, Immunotech), containing 5 µl of 20 µg/ml PI, and were analyzed via flow cytometry, acquiring 5,000 events.
DNA fragmentation assay To identify fragmented DNA, a TdT-mediated dUTP nick-end labeling (Tunel) assay was performed and assessed by cytometry (Boehringer Mannheim, Indianapolis, IN, USA). Per sample, 10 6 cells were washed in PBS and fixed in 2% paraformaldehyde for 30 min at room temperature. After fixation, the cells were washed twice in PBS containing 0.01% BSA and resuspended in TUNEL reaction mixture containing fluorescein dUTP. Fluorescein incorporated in DNA strand breaks was detected by flow cytometry.
Results

IL-2 inhibits apoptosis in resting and in stimulated B-CLL cells
Purified B-CLL cells were cultured with IL-2 100 U/ml for 48 h. Cells were either cultured in medium or together with the immunostimulatory oligonucleotide (ODN) DSP30. Apoptosis induction was modestly but significantly inhibited in resting B-CLL cells. This effect was much stronger in B-CLL cells cultured in the presence of DSP30 (Fig. 1) . The antiapoptotic effect was also evident with IL-2 at 10 U/ml and could not be increased with higher doses (data not shown). Stimulation with CpG ODN has a diverse effect on apoptosis in B-CLL cells [19, 20] . In our experimental setting, stimulation with DSP30 resulted in apoptosis induction in four of 12 samples, while an antiapoptotic effect was observed in the remaining samples (Table 1) . To be able to analyze the effect of IL-2 in CLL cells in the absence of additional signals mediated by CpG ODN, we cultured B-CLL cells for 24 h with IL-2 and CpG ODN, followed by overnight incubation in medium alone. These cells expressed the α chain of the IL-2 receptor at high levels (data not shown) and are called "CD25 high" cells in the following experiments. The antiapoptotic effect of IL-2 in these cells was much stronger than in resting B-CLL cells (Fig. 2) .
Mechanism of inhibition of apoptosis by IL-2
The mitochondrial membrane potential ΔΨ was nearly completely intact in IL-2-treated CD25 high cells. A smaller effect was observed in CD25 low cells. The intact Fig. 2 IL-2 effect on viability of CD25 low and CD25 high B-CLL cells. Annexin/PI staining was performed in seven independent samples after culture for the indicated times with medium or IL-2 at 100 U/ml. Cells were either cultured immediately after isolation (CD25 low) or after prestimulation with DSP30 and IL-2 for 24 h, followed by an overnight incubation with medium alone (CD25 high) membrane potential was strongly correlated with a reduction of DNA strand brakes, reduction of phosphatidylserine exposure, and inhibition of PARP cleavage (Figs. 3 and 4) .
In CD25 high cells, Bcl-xl expression was increased in the presence of IL-2, and no effect was observed in CD25 low cells. In contrast, MCL-1 was increased upon addition of IL-2 in both CD25 low and high cells. However, expression levels in CD25 high cells were much higher. Expression levels of Bcl-2 did not change in CD25 low cells, but Bcl-2 expression was strongly reduced in CD25 high cells and was no longer detectable if IL-2 was added.
BAX and Bak expression levels were not changed in CD25 low or high cells, but Bax cleavage was inhibited in CD25 high cells upon stimulation with IL-2. In addition, survivin expression was strongly increased in IL-2-stimulated CD25 high cells. Results are shown in Fig. 4 . Two additional experiments gave very similar results.
Akt phosphorylation in response to IL-2 in CD25 low and high cells
The Akt pathway has been demonstrated to be involved in B-CLL survival [21, 22] 2 signal transduction system [23] . Therefore, we analyzed akt phosphorylation in response to IL-2 in CD25 high and CD25 low cells. Phosphorylation at Serine 473, which is an important phosphorylation site [24] , was rapidly observed in CD25 high cells, while only marginal phosphorylation was observed in CD25 low cells upon incubation with IL-2 ( Fig. 5) . Akt phosphorylation at Serine 473 was inhibited in the presence of LY294002 (LY), an inhibitor of the PI3 kinase pathway. One representative experiment out of three performed is shown in Fig. 6 .
DIOC6(3) counts
Chemotherapy resistance of activated B-CLL cells is reverted by LY294002
Because IL-2 has a strong antiapoptotic effect in activated B-CLL cells, we were interested whether IL-2 could also confer resistance against chemotherapy in these cells. 
Discussion
The present study demonstrates that IL-2 clearly has antiapoptotic properties in B-CLL cells. The antiapoptotic effects of IL-2 are much more pronounced in activated (CD25 high) cells than in resting B-CLL cells, which is in sharp contrast to the role of IL-2 in promoting activationinduced cell death in T cells [26] . Involvement of IL-2 in the pathogenesis of B-CLL has been postulated for a long time [27] , but previous research has focused on proliferation and expression of costimulatory molecules [15] . IL-2 is mainly produced by activated T cells and is a key cytokine involved in the expansion and development of T cells, especially regulatory T cells [8] . Indeed, the overall pool of T cells is significantly increased in B-CLL cells with a high frequency of CD4 T cell expansion [28] and increased numbers of regulatory T cells correlate with disease burden [29] .
In B-CLL patients, CD3 positive T cells can be detected in clusters with survivin expressing and proliferating B-CLL cells in lymph nodes [30, 31] . In addition, autologous T cells have been shown to inhibit apoptosis in cocultured B-CLL cells [4, 17] , and we have previously demonstrated that IL-2 production by activated T cells is increased when B-CLL cells are added to autologous T cells [32] . Therefore, IL-2 might well be an important factor in the microenvironment of B-CLL cells, which is thought to be important for disease progression [33] .
In our present study, we observed a small but significant antiapoptotic effect of IL-2 in resting B-CLL cells. More important, IL-2 had strong antiapoptotic properties in our model of activated B-CLL cells (Fig. 2) .
In CD25 low cells, IL-2 prevented MCL-1 downregulation with no effect on bcl-2 expression (Fig. 5 ). Both proteins of the bcl-2 family have been described to be important for B-CLL pathophysiology [34, 35] . MCL-1 downregulation was also prevented in CD25 high cells, but bcl-2 levels declined. Reduced bcl-2 expression has been described in activated B-CLL cells previously [36] and might be a consequence of a higher percentage of B-CLL cells in S-phase of the cell cycle in our "CD25 high cells" [16, 37] . In contrast, expression of the antiapoptotic proteins bcl-xl and survivin were strongly enhanced in the presence of IL-2 in CD25 high cells. Therefore, the expression of antiapoptotic proteins in CD25 high cells treated with IL-2 strongly resembles the high bcl-xl, survivin, and MCL-1 expression in B-CLL cells in lymph nodes with proliferation centers [30, 38, 39] .
Importantly, T cells in the microenvironment may induce CD25 upregulation in B-CLL cells by providing CD40 ligand and IL-10 as well as IL-2 [14, 32] . IL-2 is then able to both induce proliferation and prevent apoptosis in the malignant cells and might therefore play a central role in the balance between proliferation and apoptosis, which is determined in lymphoid tissues [40] .
The serine threonine kinase Akt is a major effector of the PI3Kinase pathway in cancer and a central regulator of cell growth, survival, and chemotherapy resistance [41] . Akt activation is thought to be involved in B-CLL progression and has been shown to mediate resistance against chemotherapy and radiation [22] .
While no Akt activation was observed in CD25 low cells, Akt was rapidly phosphorylated in CD 25 high cells. In addition, pharmacological inhibition of Akt activation was able to restore sensitivity to fludarabine in IL-2-treated CD25 high cells (Figs. 5, 6, and 7) . In addition, IL-2 might protect these cells against the effects of cytotoxic chemotherapy. Therefore, IL-2 might be an important part of a microenvironment, suitable for expansion and survival of the malignant clone.
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